New hope for stomach cancer: targeted drug HS-20093 enters human trials
NCT ID NCT07462923
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests HS-20093, a drug designed to seek out and attack cancer cells by targeting a protein called B7-H3. It is for people with advanced stomach or gastroesophageal junction cancer that has not responded to or stopped responding to standard treatments. The study will enroll about 40 participants to check safety, tolerability, and whether the drug can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-20093 (an antibody-drug conjugate that targets B7-H3 on tumor cells)
What this could lead to
If successful, this could point toward a new treatment option for advanced gastric cancer that has stopped responding to standard therapies.
What could go wrong
This is an early Phase 1b trial with only 40 participants, so it is too small to prove effectiveness. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••